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Background: Colorectal cancer is one of the most common cancers in the United States with an early detection
rate of only 39%. Colorectal cancer cells along with other cancer cells exhibit many deficiencies in cell-to-cell
communication, particularly gap junctional intercellular communication (GJIC). GJIC has been reported to diminish
as cancer cells progress. Gap junctions are intercellular channels composed of connexin proteins, which mediate
the direct passage of small molecules from one cell to the next. They are involved in the regulation of the cell cycle,
cell differentiation, and cell signaling. Since the regulation of gap junctions is lost in colorectal cancer cells, the goal
of this study is to determine the effect of GJIC restoration in colorectal cancer cells.
Methods: Gap Junction Activity Assay and protein analysis were performed to evaluate the effects of
overexpression of connexin 43 (Cx43) and treatment of PQ1, a small molecule, on GJIC.
Results: Overexpression of Cx43 in SW480 colorectal cancer cells causes a 6-fold increase of gap junction activity
compared to control. This suggests that overexpressing Cx43 can restore GJIC. Furthermore, small molecule like
PQ1 directly targeting gap junction channel was used to increase GJIC. Gap junction enhancers, PQ1, at 200 nM
showed a 4-fold increase of gap junction activity in SW480 cells. A shift from the P0 to the P2 isoform of Cx43 was
seen after 1 hour treatment with 200 nM PQ1.
Conclusion: Overexpression of Cx43 and treatment of PQ1 can directly increase gap junction activity. The findings
provide an important implication in which restoration of gap junction activity can be targeted for drug
development.
Keywords: Gap junction intercellular communication, PQ1, Kinase activityBackground
Colorectal cancer is the third most common cancer and
the third leading cause of cancer related death in the
United States [1,2]. In 2013, approximately 136,830 people
were diagnosed with colorectal cancer. Approximately
50,310 deaths in the past year were due to colorectal
cancer [3]. Thus, understanding the etiology of colorectal
cancer is critical for the treatment of the disease.
GJIC has been shown to be decreased in cancerous cells
and at tumor borders [4,5]. Gap junctions are intercellular
channels made of the protein known as connexin. There
are 21 isoforms of connexin [6]. Six connexins make
up a connexon; two connexons, each on an adjacent
cell, interact and form a gap junction. Gap junctions* Correspondence: tnguyen@vet.k-state.edu
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article, unless otherwise stated.mediate the direct passage of small molecules (<1000 Da)
from one cell to the next [7]. They are involved in the
regulation of the cell cycle, cell differentiation, and cell
signaling [8]. The life cycle of gap junctions is regulated by
phosphorylation events [9-11].
Regulation of Cx43 in GJ formation has been shown to
be due to phosphorylation by different kinases at
multiple phosphorylation sites on the carboxy(C)-terminus
domain [9-14]. Mitogen-activated protein kinase (MAPK)
and active protein kinase B (pAKT) are known regulators
of Cx43 [12-14]. Early studies showed MAPK phosphoryl-
ation of Cx43 which leads to a decrease in GJs. However,
recent literature suggests that it can lead to an upregulation
in Cx43 causing an increase in functional GJs [13]. Another
kinase, Akt, has been shown to stabilize gap junctions via
phosphorylation, the exact site of Akt phosphorylation
Cx43 is unknown. Dunn et al., found that upon inhibitionCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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version of Akt gap junctions were smaller and less
phosphorylated Cx43 was present [15].
Phosphorylation events correlate with three known
isoforms of Cx43, the isoforms are known as P0, P1 and
P2. The P0 form localizes on internal membranes like
the Golgi apparatus and the endolysosomal system
[16,17]. The P1 and P2 forms are associated with certain
phosphorylation cites. The P1 form has phosphorylation
site at S364/S365. When phosphorylated at S365 of
Cx43, the assembly conformation of the gap junction
was observed [18]. The P2 form has two different sets of
phosphorylation sites. One of these sets is phosphorylated
at S325/S328/S330; this form has been found at the stage of
gap junctional plaques. When phosphorylated at S262
and/or S368 of Cx43, a decrease in GJIC is found [17,19,20].
Gap junction enhancers, 6-Methoxy-8-[(3-amionpropyl)
amino]-4-methyl-5-(3-trifluoromethyl-phenloxy) quinolone
(PQ1), has been demonstrated to increase gap junction
activity in breast cancer cells [21]. PQ1 caused an 8.5-fold
increase in gap junction activity in T47D breast cancer cells
and subsequently a decrease of 70% growth in a xenograft
tumor [21]. Furthermore, PQ1 has also been shown
to induce apoptosis via caspase 8 and 9 [22]. Oral
bioavailability studies indicate that administration of
PQ1 via oral gavage has a low toxicity to normal tissue
with no observable adverse effects [23], while significantly
attenuating tumor growth [21].
As colorectal cancer forms, there is a decrease in gap
junction activity and Cx43 expression as well as a shift
in localization of Cx43 [4,5,24]. Thus, this study
addresses whether overexpression of Cx43 or increase
gap junction activity can be achieved in human colorectal
cancer cells, SW480. Using overexpression of Cx43 and
treatment of PQ1 approaches, the gap junction activity of
SW480 cells was restored. Overall, this study provides
evidence for the first time that regain of GJIC can be
achieved by a small molecule gap junction enhancer, PQ1,
on SW480 colorectal cancer cells.Methods
Ethics statement
All experiments in this manuscript have been approved
by the Kansas State University Institutional Biosafety
Committee (IBC).Cell Line
The SW480 human colorectal cancer cell line was
purchased from American Type Cell Culture (ATCC,
Manassas, VA). Cells were grown with 0% CO2 in
Leibovitz’s L-15 Medium with 10% Gibco Fetal Bovine
Serum (FBS) purchased from Life Technologies (Grand
Island, NY, USA).Western blot
Cells were seeded to 50% density in a T-25 cm2 flask for
24 hours and allow the density to reach 90% prior to
treatment. cells were harvested with lysis buffer (20 mM
Tris–HCl pH 7.6, 0.5 mM EDTA, 0.5 mM EGTA, and
0.5% Triton-X 100) (Cell Signaling Technology Inc.,
Danver, Massachusetts, USA). The mixture was centrifuged
at 13,000 rpm (15,700 g using an Eppendorf centrifuge
5415R with rotor F-45-24-11, Eppendorf North America,
Hauppauge, New York, USA) for 30 minutes at 4˚C, and
the supernatant was collected. Total protein concen-
tration was determined using a Bio-Rad protein assay
kit (Bio-Rad Life Science Research, Hercules, California,
USA). 25 μg of whole cell extract was separated by
5-10% sodium dodecylsulfate (SDS) polyacrylamide gel
electrophoresis (PAGE) and transferred onto a nitrocellu-
lose membrane. The nitrocellulose membrane was immu-
noblotted against the protein of interest. The primary
antibodies were purchased from two different companies;
mouse anti-Cx43 antibody and the mouse anti-GAPDH
antibody were purchased from Santa Cruz Biotechnology
(Santa Cruz, California, USA). Primary antibodies
purchased from Cell Signaling Techonolgy (Danvers,
Massachusetts, USA) were; rabbit anti-phospho-Akt and
rabbit anti-phospho-p44/42 MAPK. Secondary antibodies
were anti-mouse and anti-rabbit IGg HRP linked, they
were purchased from Cell Signaling Technology (Danver,
Massachusetts, USA). Proteins were detected using the
FluorChem E System purchased from Protein Simple
(Santa Clara, California, USA).
Transfection
Eight hundred thousand SW480 cells were seeded into
six-well plates for 24 hours. Cells were transfected with
3.5 μg of Gja1, NM 012567.2, subcloned into pEGFP-N3
vector [25] and Optifect reagent in 0% FBS tissue culture
media.
Gap junction activity
Scrape Load/Dye Transfer (SL/DT) assay was used to
measure gap junction activity. Eight hundred thousand
cells were grown on a cover slip in a six-well plate. Cells
were grown for 24 hours; cells designated for overexpres-
sion of Cx43 were transfected, 24 hours later treatments
of 200 nM 12-O-Tetradecanoylphorbol-13-Acetate (TPA)
and/or with 50 nM, 200 nM and 500 nM PQ1 for 1 hour.
Cells were then washed with Phosphate Buffered Saline
(PBS) 3 times. A mixture of 1% Lucifer yellow and 0.75%
Rhodamine dextran was added in the center of the cover
slip. Two cuts crossing one another in the center of the
coverslip were made. After 3 minutes, cells were washed
with PBS 3 times and incubated at 37˚C in tissue culture
media for 20 minutes. The cells were then washed with
PBS and fixed with 2.5% paraformaldehyde for 30 minutes.
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visualized under a fluorescent microscope (Nikon
Eclipse 80i, Nikon Instruments, Melville, NY, USA)
(X-Cite 120 PC fluorescence illumination system, EXFO
Photonic Solutions Inc., Mississauga, Ontario, Canada) at
10x objective (Nikon Instruments, Melville, NY, USA).
Images were captured using Nikon Digital Sight Fi1
(Nikon Instrument, Melville, NY, USA). The distance
between the designated cut and the dye transfer was
measured. The distance of dye uptake indicates that
cells are active and have allowed the dye to pass from
one cell to the next cell.
Proliferation and viability
Eight hundred thousand cells seeded into 6-well plates for
24 hours. Cells were treated with PQ1 at various concen-
trations or overexpressed with Cx43. After another 24, 48
or 72 hours tissue culture media of respective treatments
was saved and 0.5 mL of trypsin was added to the cells for
5 minutes. Three mL of PBS was used to harvest cells.
Cells were spun down for 5 minutes at 13,000 rpm;
afterwards solution of tissue culture media, trypsin
and PBS was removed. Nine hundred μL of PBS and
100 μL of trypan blue were added to the pellet andFigure 1 Overexpression of Cx43 increases gap junction activity. Cells
Vector (control), transfection of Cx43 for 24 hours. Level of Cx43 and its iso
loading control. A) Levels of Cx43 were examined using anti-connexin43 (F-7
B) Graphical presentation of three independent experiments showing pixel in
Load/Dye transfer assay (SL/DT) was performed after no transfection and the
in white. Red line indicates the point of entry for Lucifer yellow. D) Gr
P2 from panel A. Data were obtained in three independent experiments and
IB = Immunoblot against Cx43.left to stand for 5 minutes. Cellometer Auto 2000
from Nexcelom Bioscience was used to measure number
of cells for proliferation and viability.
Statistical analysis
Pixel intensities of protein bands were normalized to
pixel intensities of loading control (GAPDH). All protein
expression data were expressed as mean ± standard
deviation of three independent experiments. Significant
differences were analyzed by comparing the data of treated
samples and control (untreated) samples and indicated as
P value > 0.05 using Student’s t-test.
Results
Transfection of Cx43 leads to increased GJIC in SW480
colorectal cancer cells
Intercellular communication in many organs is maintained
via GJIC. An effective clinical drug targeting GJIC has not
been studied for colorectal cancer at this time; thus, ways
to increase GJIC in colorectal cancer cells were examined.
Cells were transfected with Cx43 expression plasmid for
24 hours. Western blot analysis shows that 25 ug of
Cx43 expression vector was sufficient to increase
Cx43 in SW480 cells compared to control or emptywere treated with: no transfection (control), transfection of Empty
forms were examined by western blot analysis. GAPDH was used as a
) antibody specific for amino acids 357–381 at the C-terminus domain.
tensities of total Cx43 normalized to Empty Vector (control). C) Scrape
transfection of overexpression of Cx43. Lucifer yellow dyes in cells indicate
aphical presentation shows the ratio of Cx43 isoforms P0, P1 and
are represented as the mean ± SD. *P value is <0.05 compared to control.
Figure 2 Overexpression of Cx43 causes a decrease in viability of SW480 cells. Eight hundred thousand cells were seeded into six-well
plates. Cells were transfected with optifect for 24 hours. Transfection conditions were: Control, Empty Vector, and Cx43 vector. After 24 hours,
viability and proliferation assays were performed. A) Proliferation of SW480 cells. B) Viability of SW480 cells. Data were obtained in three independent
experiments and are represented as the mean ± SD.
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for gap junction activity after 24 hours of transfection. The
results showed a 6-fold increase of gap junction activity
in Cx43-transfected cells compared to control cells
(Figure 1C). Thus, these suggest that regain of GJIC in
SW480 cells can be achieved via transfection of Cx43. Fur-
thermore, differential pattern of Cx43 isoform was
observed. The protein blot analysis shows that there are
three distinct isoforms of Cx43: P0, P1, and P2. IsoformFigure 3 PQ1 causes an increase in gap junction activity of SW480 ce
SL/DT assay was performed after the following conditions: A) SW480 cells w
B) SW480 cells were treated with 50 nM PQ1, 200 nM PQ1 and 500 nM PQ1 f
TPA + 200 nM PQ1 for 1 hour; and D) SW480 cells were treated with 1
Lucifer yellow indicated in white and the point of entry for Lucifer yel
independent experiments.expression of Cx43 has shifted from P0 form to P1
form in the Cx43 transfected cells (Figure 1D). Overall
these results show an increase in GJIC by overexpression
of Cx43.
The effects of overexpression of Cx43 on cell viability
and proliferation were analyzed. Proliferation study of
SW480 cells, overexpressed with or without the
Cx43 expression vector, show a decrease of 20%
compared to control (Figure 2A). Viability of SW480lls. Eight hundred thousand cells were seeded into six-well plates.
ere treated with no treatment (control) and DMSO (control) for 1 hour;
or 1 hour; C) SW480 cells were treated with 200 nM TPA and 200 nM
00 μM CBX and 100 μM CBX + 200 nM PQ1 for 1 hour. Cells with
low indicated by red line. These images represent one set of three
Figure 4 PQ1 changes isoform expression of Cx43. Cells were treated with: no treatment (control), DMSO (control), 200 nM PQ1, 200 nM TPA
and 200 nM PQ1 + 200 nM TPA for 1 hour. Level of Cx43 and its isoforms were examined by western blot analysis. GAPDH was used as a loading
control. A) Levels of Cx43 were detected using anti-connexin43 (F-7) antibody specific for amino acids 357–381 at the C-terminus domain. B)
Graphical presentation of three independent experiments showing pixel intensities of total Cx43 normalized to control. C) Graphical presentation
shows the ratio of Cx43 isoforms P0, P1 and P2. Data were obtained in three independent experiments and are represented as the mean ± SD.
*P value is <0.05 compared to control. IB = Immunoblot against Cx43.
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by 4% (Figure 2B). These data demonstrate that the
transfection did not alter the proliferation and viability of
SW480 cells and the change in gap junction activity is due
to the overexpression of Cx43.Figure 5 Immunofluorescence of SW480 cells. Eight hundred thousand
no treatment (control), DMSO (control) and 200 nM PQ1. ImmunofluorescePQ1, gap junction enhancer, increases GJIC in SW480
colorectal cancer cells
The approach of increasing GJIC directly has potential to
enhance the efficacy of cancer treatment. Since transfecting
all cancer cells with Cx43 is not valid as a therapeuticcells were seeded into six-well plates. SW480 cells were treated with
nce was performed after 1 hour of PQ1 treatment.
Figure 6 PQ1 causes activation of Akt. Cells were treated with: no treatment (control), DMSO (control) and 200 nM PQ1 for 1 hour. Level of
phospho-Akt (active Akt) was examined by western blot analysis. GAPDH was used as a loading control. A) Level of active Akt was detected using
anti-phospho-Akt (Ser473) (D9E) antibody specific for activated Akt. B) Graphical presentation of three independent experiments showing pixel
intensities of active Akt normalized to control. *P value is <0.05 compared to control. IB = Immunoblot against phospho-Akt.
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junction enhancers, a class of substituted quinolines (PQs),
have shown to increase GJIC in other cancer cells. Thus, in
this study PQ1 was used to increase GJIC in SW480
colorectal cancer cells. SW480 cells were treated with PQ1
at concentrations of 50 nM, 200 nM and 500 nM for
1 hour. The gap junction activity was measured by scrape
load/dye transfer assay. The results show that cells treated
with 200 nM PQ1 have a 4-fold increase of dye transfer
compared to control cells without treatment or solvent
alone (Figure 3A and B). Interestingly, cells treated with
PQ1 and GJ inhibitor, TPA, have no increase of gap
junction activity compared to control, suggesting that TPA
blocks PQ1-mediated GJIC in SW480 cells (Figure 3C).
Carbenoxolone (CBX) is a known gap junction inhibitor;
thus, it was used as a control to see if PQ1’s effects directly
affect the gap junction. CBX is thought to effect the gap
junctions by altering local lipid environment [26]. The
effects of CBX on the bilipid layer membrane conductance
were not studied in this paper. Results show that treatment
with 100 μM CBX+ 200 nM PQ1 did not show an increase
in GJIC when compared to 100 μM CBX alone or controls
(Figure 3A and D). This concludes that PQ1 cannot open
GJs in the presence of a GJ inhibitor.Previously, PQ1 was constructed using the structure of
the c-terminus of Cx43 [21]. Western blot analysis was
used to analyze the effects of PQ1 on gap junction
protein Cx43. Figure 4B shows the protein expression of
Cx43 after treating with 200 nM PQ1 and/or 200 nM
TPA for 1 hour. Results show no significant change in
total Cx43 expression after treatment with PQ1 for
1 hour (Figure 4A and B). However, treatment with 200
nM TPA for 1 hour decreases expression of Cx43 by
30% (Figure 4A and B). These data are consistent with
the findings by Oh et al., demonstrating that TPA leads
to a decrease in Cx43 expression [27]. Figure 4C shows
Cx43 isoform expression in treated cells compared to
control cells. After treatment for 1 hour with 200 nM
PQ1 a shift in isoform expression was seen from P0 in
control cells to P2 as the dominant form in PQ1 treated
SW480 cells (Figure 4A and C). The expression of the
P2 form increased 2-fold after treatment with 200 nM
PQ1 for 1 hour (Figure 4A and C). The P0 form decreased
2-fold and the P1 form had no change after PQ1 treatment.
When treating cells for 1 hour with 200 nM TPA, the
isoform profile of Cx43 shows no significant change in the
expression of the P2 or P1 isoforms of Cx43 compared to
control. The P0 isoform was seen to decrease 2-fold with
Figure 7 PQ1 leads to p44/42 MAPK expression. Cells were treated with: no treatment (control), DMSO (control) and 200 nM PQ1 for 1 hour.
Levels of phospho-p44/42 MAPK (active p44/42 MAPK) expression was examined by western blot analysis. GAPDH was used as a loading control.
A) Level of active p44/42 MAPK was detected using anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody specific for endogenous active
p44/42 MAPK. B) Graphical presentation of three independent experiments showing pixel intensities of active p44/42 MAPK normalized to
control. *P value is <0.05 compared to control. IB = Immunoblot against phosphor-p44/42 MAPK.
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isoform. However, there was no significant change in
isoform expression after treatment with both TPA and
PQ1 for 1 hour, suggesting a potential antagonistic
relationship between PQ1 and TPA. Immunofluorescence
was used to visualize Cx43 localization after 200 nM PQ1
treatment for 1 hour compared to no treatment and DMSO
controls. Results show a shift from Cx43 localization in the
cytoplasm to Cx43 gap junctional plaques after PQ1
treatment (Figure 5). Overall, these findings suggest
that PQ1’s ability to increase GJIC is by acting on the
existing Cx43 and not by increasing Cx43 expression.
PQ1’s effects on Kinase activity
Since specific kinases phosphorylate Cx43 and lead the
change in gap junction activity, this study focuses on key
kinases involving the PQ1-mediated GJIC. The activated
form of Akt and p44/42 MAPK were analyzed. After
1 hour of treatment with PQ1, activated Akt increases
by 100% compared to control (Figure 6). This suggests
that increasing gap junction activity by PQ1 may involve
the activation of Akt.Furthermore, MAPK was examined due to the fact that
MAPK can phosphorylate Cx43 and subsequently increase
gap junction activity. The results show that an increase of
250% in activated form of MAPK (p44/42) was detected in
the presence of 200 nM PQ1 at 1 hour treatment compared
to controls (Figure 7). This provides the initial evidence that
PQ1 may also involve in the activation of p44/42 MAPK
and subsequently increase GJIC in SW480 cells.
As PQ1’s activation of Akt and p44/42 MAPK may be
independent of gap junctions, cells were pre-treated with
kinase inhibitors calphostin C and staurosporin prior to
treatment with 200 nM PQ1 for 1 hour. Figure 8 shows
that in the presence of kinase inhibitors PQ1 does not
cause an increase in GJIC compared to PQ1 treatment
alone. This suggests that PQ1 leads to an increase in GJIC
via kinases. The inhibitors used are specific to PKC so in
the future inhibitors for MAPK and Akt will be used to test
PQ1’s ability to increase GJIC without MAPK and Akt.
Discussion
In colorectal cancer, a decrease in GJIC has been found.
In this study, overexpression of Cx43 increased GJIC
Figure 8 PQ1’s effects on GJIC in the presence of kinase inhibitors. Eight hundred thousand cells were seeded into six-well plates. A) SW480
cells were treated with no treatment (control) and DMSO (control) for 1 hour. B) SW480 cells were pre-treated with kinase inhibitors (Calphostin
C or Staurosporin) for 1 hour. After pre-treatment, cells were treated with 200 nM PQ1 for 1 hour. SL/DT was preformed after 1 hour of PQ1 treatment.
Cells with Lucifer yellow indicate in white and the point of entry for Lucifer yellow indicates in red line. These images represent one set of three
independent experiments.
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(Figure 1). It was shown that overexpression of Cx43
lead to a change in isoform expression from P0 to P1
leading to an increase in GJIC. This suggests that the
SW480 cells have the key kinases needed to regulate
GJIC. Other approach of increasing GJIC was also
evaluated since transfection of Cx43 is not a viable
therapeutic target. A small molecule, PQ1, was tested
as a potential GJ enhancer in SW480 colorectal cancer
cells. The results show that PQ1 can increase gap junction
activities.
Gap junctions allow for intercellular communication
between adjacent connecting cells. GJs play a major role
in the life cycle of cells; they are involved in tissue
homeostasis and proliferation as well other aspects of
the cell cycle [28-30]. In cancer cells, there is a significant
change of Cx43 localization at the plasma membrane and
the cytoplasmic membrane such as the golgi apparatus
and the endolysosomal system [18,24]. PQ1, does not
cause an increase in Cx43 expression, it causes a shift in
the isoform expression causing Cx43 to once again be
localized to the plasma membrane and to form functional
gap junctions (Figures 4B and C and 5).
The regulation of gap junctions is controlled by
phosphorylation of specific sites (mostly serine sites)
on the carboxy-terminal tail region of the connexins[31]. Previously, Akt and MAPK have demonstrated
to modulate Cx43 phosphorylation and subsequently
increase gap junction activity. Active Akt has been
found to stabilize gap junctions and active p44/42
MAPK has been shown to increase GJIC [12,13]. This
study was also determined whether the increase of
gap junction activity by PQ1 was due to the activation of
Akt and MAPK. Interestingly, PQ1 was shown to cause an
increase in activated Akt and p44/42 MAPK (Figures 6
and 7). This suggests the possibility that PQ1’s ability to
increase GJIC is through activation of Akt and MAPK.
PQ1’s ability to increase GJIC by kinase activity was tested
using kinase inhibitors (Figure 8A and B). Results show
that the increase in GJIC by PQ1 is at least in part due to
kinase activity (Figure 8A and B).
Conclusions
We have shown that GJIC can be restored via overex-
pression of Cx43 and by small molecule PQ1. PQ1 was
shown to cause an increase in GJIC by changing the
isoform expression of Cx43. Since PQ1 was designed
using the structure of the c-terminus of Cx43 a potential
mechanism may by direct binding to the c-terminus of
Cx43. However this study has provided evidence of
PQ1’s ability to cause an activation of Akt and p44/42
MAPK and subsequently increase GJIC in SW480 cells.
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of PQ1 on specific site of phosphorylation of Cx43.
Overall, the initial data provide insight into PQ1 being a
mediator of kinase activity and via this activity cause an
increase in GJIC of colorectal cancer cells. These data
also conclude that PQ1 is a GJ enhancer in the SW480
colorectal cancer cells. This leads to the possibility of
PQ1 being able to enhance the effects of current chemo-
therapeutic drugs by way of gap junctions.
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